Self-guided

<5 minutes

FEV1 Percent Predicted Is a Marker of Lung Health in Pediatric Asthma

Topic: Burden Of Disease Pathophysiology Guidelines & recommendations

Tags: Disease burden  Exacerbations  Lung function  Pathophysiology  Type 2 inflammation  Biomarkers  FEV1pp  Pediatric asthma 

FEV1 Percent Predicted Is a Marker of Lung Health in Pediatric Asthma

Learn how FEV1pp can be used to manage asthma in pediatric patients and understand future risks associated with reduced FEV1pp and pediatric disease severity.

 

 

 

 

MAT-US-2201151  V1 03/15/2024

Welcome to the ADVENT program website

ADVENT is a medical education program by Sanofi and Regeneron. This website is intended only for health care professionals in the US only.

I AM A HEALTHCARE PROVIDER
I AM NOT A HEALTHCARE PROVIDER

ADVENT is a global medical education program by Sanofi and Regeneron and is only intended for healthcare providers.

You are leaving the ADVENT program website

Sanofi Genzyme does not review or control the content of non–Sanofi Genzyme websites, and this hyperlink does not constitute an endorsement by Sanofi Genzyme of the site’s content. Sanofi Genzyme’s privacy procedures do not apply to the owners of a non–Sanofi Genzyme website.

LEAVE THIS SITE GO BACK TO ADVENT PROGRAM
x

STAY IN THE KNOW

Would you like to receive updates on new ADVENT content, courses and events when available?

SUBSCRIBE

MAT-US-2104233 Exp 04/26/2023

x

Congratulations, you are now subscribed successfully.

You will receive a confirmation email at the address you provided.

If you don’t receive it, please check your spam.